Physician profile
Paul Plante
NPI 1508825464
$7,899.67
in general payments reported to CMS, 2019-2025
53 companies · $965 in 2025
The $965 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $1,060 · 2021: $1,403 · 2022: $1,123 · 2023: $1,161 · 2024: $1,050 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,029.44 | 2019-2025 | Farxiga, Fasenra, Breztri |
| Abbvie INC. | $957.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.16 | 2019-2025 | Jardiance |
| Amgen INC. | $441.84 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $397.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $394.32 | 2019-2025 | |
| Lilly USA, LLC | $383.18 | 2019-2024 | Jardiance, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $301.93 | 2019-2025 | Trintellix |
| Insulet Corporation | $291.94 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $286.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $245.60 | 2019-2023 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $237.70 | 2022-2025 | Zoryve |
| Glaxosmithkline, LLC. | $225.27 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $221.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $220.60 | 2019-2023 | Belsomra, Steglatro |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Plante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.